Aktis Oncology, Inc. (AKTS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Aktis Oncology, Inc. (AKTS) closed at USD 16.49 on 2026-10-14, a change of -26.4 % over the past year, with a market capitalization of USD 890.47M.

Aktis Oncology, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Aktis Oncology, Inc. key figures

Previous close

USD 16.49 (2026-10-14)

1-year change

-26.4 %

Market cap

USD 890.47M

Enterprise value

USD 384.39M

P/E ratio (trailing)

-9.82

P/E ratio (forward)

-7.50

EPS (trailing)

-1.63

EPS (forward)

-2.14

PEG ratio

n/a

Price to book

1.83

Revenue growth

111.4 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

10.11

Employees

79

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Aktis Oncology, Inc.

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Aktis Oncology, Inc. and compare it with other stocks.